Editorial Article: 5 cell and gene therapy webinars to watch on demand

Expert webinars to explore the latest research and challenges in cell and gene therapy development

18 Nov 2022

As the field of cell and gene therapy expands, there is a growing demand to develop solutions that streamline the characterization and analysis of these therapeutics. Here discover some of our recent expert-led webinars in the field of cell and gene therapy covering the latest research into chimeric antigen receptor (CAR)-T cell therapies targeting renal cell carcinoma and pediatric brain tumors and discover solutions for the characterization of gene therapy vectors including lipid nanoparticle (LNP) lentivirus and adeno-associated virus (AAV) characterization.

Image of cancer cells dividing

Designing CAR-T cell therapy for clear cell renal cell carcinoma

CAR-T cell therapy has proven to be a powerful immunotherapy for hematologic malignancies. However, this success has not yet been transferred to solid tumors due to inefficient homing of CAR-T cells, the immunosuppressive tumor microenvironment (TME), and on-target off-tumor toxicities due to the shared epitopes on healthy tissues. The tumor associated antigen carbonic anhydrase IX (CA-IX) is overexpressed on clear cell renal cell carcinomas (ccRCC) and many other solid tumors. Watch this webinar to learn how engineered anti-CA-IX targeted CAR-T cells secreting human anti-programmed death ligand 1 (PDL-1) antibodies at the tumor site restore active anti-tumor immunity.

Watch webinar

Image of immune cells attacking cancer cells

A potent therapeutic strategy for diffuse midline glioma H3K27M mutant

This webinar explores the potential use of GD2-CAR T-cells as a therapeutic strategy in treating aggressive pediatric brain tumors that have a poor prognosis and limited treatment options: Diffuse midline gliomas (DMG) H3K27M mutant, including diffuse intrinsic pontine glioma (DIPG). Learn how Dr. Maria Vinci and the team at Bambino Gesù Children’s Hospital, in Italy, developed a high-throughput cell-based assay to screen 42 kinase inhibitors in combination with GD2-CAR T-cells.

Watch webinar

Image of DNA and puzzle pieces

A next-gen solution for lentivirus characterization

LentiView is a novel assay capable of providing rapid and actionable data on lentivirus size, empty/full ratio, viral titer, and pseudotype characterization without the need for sample purification. In this webinar, learn how LentiView is used in combination with the fully automated ExoView R200 imaging platform for simple sample processing, data acquisition, and analysis.

Watch webinar

Image of DNA helix

Ensuring AAV vector quality

Discover a method for highly specific and reproducible quantification and sizing of HEK293 residual host cell DNA with an extraction-free protocol. In this webinar we will learn how AAV vectors are used in gene therapy and how to ensure their quality. We will also explore how host cell residual DNA (rDNA) can occur and why it is important to detect this in gene therapy vectors.

Watch webinar

Abstract image of DNA

Optimize LNP development

Making the perfect LNP takes skills. Testing flow rates and formulations one-by-one and looking for the right sized LNP takes up time and wastes precious payloads. Scale-up often takes a whole new workflow and turns research on the next great therapy into a constant fight. In this webinar, learn how Unchained Labs’ Nunchuck’s high-efficiency microfluidic mixer design rapidly combines the aqueous and organic phases, creating LNPs with low polydispersity, narrow particle distributions, and high encapsulation efficiency.

Watch webinar

We hope you found these cell and gene therapy webinars informative and helpful. Join our biopharmaceutical community for free today to receive direct email communications about future upcoming webinars, eBooks and other exciting updates in this field. You’ll also receive our regular newsletter bringing you the latest biopharma-related technology updates.


Images in this article are the copyrighted property of 123RF.com, its contributors or its licensed partners and are being used with permission under the relevant license.